Caricamento...
In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?
The future biosimilar insulin marketplace could be a bane, benefit, or something in between, to patients under our care in the United States. Formulary preferred product status, with or without FDA interchangeability designation, coupled with current and proposed state pharmacy substitution laws may...
Salvato in:
| Pubblicato in: | J Diabetes Sci Technol |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5032938/ https://ncbi.nlm.nih.gov/pubmed/26817993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296816629488 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|